nuclear factor kappa light chain enhancer of activated B cells
Gliclazide reduced oxidative stress, inflammation, and bone loss in an experimental periodontal disease model.
The purpose of this study was to evaluate the effect of gliclazide on oxidative stress, inflammation, and bone loss in experimental periodontal disease model.Male albino Wistar rats were divided into no binder, binder, and a ligature with 1, 5, and 10 mg / kg of gliclazide group , Maxillary fixed and scanned using micro-computed tomography to measure linear and bone volume / tissue volume (BV / TV) and volumetric bone loss.
Histopathology, the analysis of immunohistochemistry and immunofluorescence performed to test the matrix metalloproteinase-2 (MMP-2), cyclooxygenase 2 (COX-2), cathepsin K, member activator receptor nuclear factor kappa-Β ligand (RANKL), an activator receptor nuclear factor kappa-Β (RANK), osteoprotegerin (OPG) pathway, the migration of macrophage inhibitory factor (MIF), superoxide dismutase-1 (SOD-1), glutathione peroxidase-1 (GPx-1), NFkB p 50 (cytoplasm), NLS NFkB p50 (signal nuclear localization), PI3 kinase and AKT staining. Myeloperoxidase activity, malondialdehyde and glutathione levels, while interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) levels were evaluated by ultraviolet-visible spectroscopy analysis.
A reverse transcription quantitative polymerase chain reaction was used to measure gene expression of nuclear factor kappa B subunit p50 (NF-kB p50), phosphoinositide 3-kinase (PI3K), protein kinase B (AKT) and F4 / 80.Micro tomography -computed showed that 1 mg / kg of gliclazide treatment reduces bone loss is linear compared with a ligature, 5 mg / kg of gliclazide, and 10 mg / kg of gliclazide treatment.
All concentrations of gliclazide increase bone volume / tissue volume (BV / TV) compared with a binder. Treatment with 1 mg / kg of gliclazide reduce myeloperoxidase activity, malondialdehyde, IL-1β and TNF-α levels (P ≤ 0.05), and results in weak staining for COX-2, cathepsin K, MMP-2, RANK, RANKL , -1 SOD, GPx-1, MIF and PI3K. Furthermore, down-regulation of NF-kB p50, PI3K, Akt, and F4 / 80 were observed, and OPG strong staining after treatment 1 mg / kg of gliclazide treatment.This decreased migration of neutrophils and macrophages, decreased inflammatory response, and decreased bone loss in rats with ligature-induced periodontitis.
Gliclazide reduced oxidative stress, inflammation, and bone loss in an experimental periodontal disease model.
Preventing gliclazide 5-FU-Induced Oral Mucositis by Reducing Oxidative Stress, Inflammation, and P-Selectin Adhesion Molecules.
Oral mucositis (OM) is one of the main side effects of the treatment of head and neck cancers, particularly radiotherapy and / or chemotherapy. OM is characterized by ulcers, erythema, dysphagia, xerostomia, and increased susceptibility to opportunistic infections. In the perspective of finding a pharmacological therapy to prevent inflammation and ulceration of the OM, the investigation of the pleiotropic effects of commercial drugs are needed, including gliclazide, antidiabetic drugs.
This study aimed to evaluate the effect of gliclazide in experimental models of OM induced by 5-fluorouracil. male hamster pre-treated with oral gliclazide (1, 5, or 10 mg / kg) for 10 days. Cheek pouch samples were subjected to histopathological and immunohistochemical analysis (COX2, iNOS, MMP-2, NF P65, GPx) and imunofluorescence (P-selectin). IL-1β and TNF-α levels, Myeloperoxidase activity (MPO) and the level of malondialdehyde (MDA) was investigated by ultraviolet-visible spectroscopy analysis.
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF, ChIP; Recommended dilution: WB:1:500-1:5000, IHC:1:100-1:500, IF:1:50-1:500
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:500-1:5000, IHC:1:5-1:20
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, IP, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IP:2-5ug/mglysate.ELISA:1/10000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/40000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse. This antibody is Unconjugated. Tested in the following application: WB, IHC, IF, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IF:1/200-1/1000.ELISA:1/40000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/20000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC:1/100-1/300.ELISA:1/5000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/20000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/20000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human. This antibody is Unconjugated. Tested in the following application: WB, ELISA;WB:1/500-1/2000.ELISA:1/20000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;ELISA:1:1000-1:2000, WB:1:200-1:1000
Description: A polyclonal antibody against NFKB1. Recognizes NFKB1 from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:500-1:5000, IHC:1:25-1:100
Description: Boster Bio Anti-NFkB-p105 (Ab-927) NFKB1 Antibody (Catalog # A00283-1). Tested in WB, IF applications. This antibody reacts with Human, Mouse, Rat.
NLS NF P50 protein levels were analyzed by western blotting. The group treated with gliclazide at a dose of 10 mg / kg showed the presence of erythema, there was no evidence of erosion, and the absence of mucosal ulceration with a score of 1 (1-2) (p <0.01).
